1. Introduction {#sec1}
===============

Cancer is the leading cause of death worldwide, and its etiology occurs at the DNA, RNA, and protein levels. It is a very complex disease involving cascades of spatial and temporal changes in genetic networks and metabolic pathways \[[@B1]\]. Weinberg summarized the important cancer hallmarks \[[@B2], [@B3]\]. Cancer hallmarks can highlight important cancer mechanisms. In recent years, many systems biology approaches have been applied to study cancers \[[@B4]--[@B9]\]. We performed a series of studies on cancer using systems biology approaches. Recently, we have particularly focused on searching for network biomarkers of cancers \[[@B10]--[@B16]\].

Hepatocellular carcinoma (HCC) is a major liver tumor (\~80%), besides hepatoblastomas, angiosarcomas, and cholangiocarcinomas. Compared to other types of cancer, liver cancer is the third most deadly cancer globally and caused about 700,000 deaths in 2011 \[[@B17]\]. Due to the increasing annual incidences \[[@B18]\] and poor 5-year survival rate (\~15%), diagnosis and prognosis of HCC are still important public health issues. Various studies revealed a multistep process involved in liver carcinogenesis \[[@B19]\]; however, the exact biology of HCC remains poorly understood overall \[[@B20]\]. In addition, late confirmation of the occurrence of HCC through traditional histological examinations and tumor sections contributes to the poor survival rate. To accurately diagnose the occurrence of HCC at an early time, it is necessary to understand the cellular and molecular mechanisms of HCC \[[@B20]\]. Hence, in this study, we compared the early and late stages of molecular interaction networks of HCC to reveal the underlying mechanisms of HCC development.

Although the histological and molecular features leading to HCC initiation are still poorly understood, mounting evidence suggests that a gradual accumulation of mutations and genetic changes in hepatocytes, which form the live lobule, may lead to the development of HCC \[[@B21]\]. Exposure to risk factors for liver cancer, such as obesity \[[@B22]\], alcohol addiction, aflatoxin, or hepatitis viruses \[[@B21]\], and the subsequent induction of inflammation may cause advanced hepatocyte necrosis. The recurrence of necrosis and regeneration of hepatocytes provide an opportunity for the introduction of mutations and genetic changes in hepatocytes. During these processes, alternative ways to protect liver lesions occur such as fibrosis and cirrhosis. Although a high correlation between cirrhosis and an HCC diagnosis was reported, the mechanisms of how cirrhosis transforms into HCC are still unknown. Furthermore, after a definite diagnosis of HCC, patients with early-stage liver cancer have better survival rates than those in the late stage. Although HCC\'s management has substantially changed in the past few decades, the only systemic standard of care for patients with advanced HCC is sorafenib, a multikinase inhibitor, with a mean survival benefit of only 3 months \[[@B20], [@B23]\]. With advances in affordable, high-throughput technologies, increasing numbers of systems biology studies of HCC diagnoses \[[@B24]\] and treatments \[[@B25]\] have shed light on applications of systems biology to HCC diagnosis, prognosis, and therapy.

As for different etiologies and heterogenic genomic alterations of HCC, the systems biology methodology that integrates Omics data is suitable to develop accurate diagnoses, novel therapeutic targets, and efficient targeted therapies \[[@B26]\]. In this study, NGS data were used to construct protein-protein interaction (PPI) networks (PPINs) of the early and late stages of HCC. The network structure and protein associations of different stages of HCC were compared to obtain a set of significant proteins which play important roles in processes of the progression of HCC.

Chen et al. developed a dynamical network biomarker (DNB) that can serve as a general early-warning signal to indicate an imminent bifurcation or sudden deterioration before the critical transition occurs, which means that it can identify a predisease state using time series microarray data \[[@B27]--[@B29]\]. We tried a different approach from their method and used sample microarray data from liver cancer patients at different stages. Our approach could also be extended to predict some similar results as their research. That is, in this study, we simply divided the cancer into early and late stages, but there are more stages of cancer, such as stages I, II, III, and IV. If we could observe the time evolution of cancer biomarkers at these other different stages, we could also predict the predisease state by comparing these cancer biomarkers at different stages.

We reveal the carcinogenesis process from early-stage and late-stage liver cancer. A specific pathway of the early stage was the mismatch repair pathway, while specific pathways of the late stage were the spliceosome pathway, lysine degradation pathway, and progesterone-mediated oocyte maturation pathway.

2. Materials and Methods {#sec2}
========================

2.1. Overview of the Process for Constructing Liver Cancer Network Markers {#sec2.1}
--------------------------------------------------------------------------

We successfully used our methods to find core and specific network markers of four different kinds of cancer and the evolution of network markers from the early stage to late stage of liver cancer \[[@B15], [@B16]\]. A similar theoretical framework was employed in this study to find the evolution of network markers in the early and late stages of liver cancer. The theoretical systems method in this paper was developed from a previous study, but we used a new large dataset of NGS expression data which differ from traditional microarray expression data. A flowchart of the construction of network biomarkers for the early and late stages of liver cancer is shown in [Figure 1](#fig1){ref-type="fig"}. We know that a lot of NGS gene expression data have been generated in recent years. Some consider that they are more accurate than traditional microarray expression data. Another key point of this work was to make comparisons with our previous results, such as network biomarkers of liver cancer from microarray data and the evolution of network markers from the early and late stages of liver cancer. We combined two data sources: (1) NGS data of liver cancer and noncancer samples from the GEO database, among which cancer samples were divided into two groups of early-stage and late-stage liver cancer, and (2) the PPI database, which is required to construct PPINs for liver cancer. These data were used for PPI pool selection, and the selected PPIs and microarray data were then used for PPIN construction. Through regression modeling and the maximum-likelihood parameter estimation method, a cancer PPIN (CPPIN) and noncancer PPIN (NPPIN) were obtained. We also constructed a differential PPIN (DPPIN). The constructed CPPIN and NPPIN were compared to obtain a set of significant proteins for liver cancer based on the carcinogenesis relevance value (CRV) for each protein and a statistical assessment. Significant proteins and PPIs among these proteins were used to construct network markers for the early and late stages of liver cancer.

2.2. Data Selection and Preprocessing {#sec2.2}
-------------------------------------

Liver RNA-seq data were collected from liver HCC (LIHC) of The Cancer Genome Atlas (TCGA) with a batch number of 100. Normalized results, which consisted of reads per kilobase of exon per million mapped reads (RPKM) values, were used to represent gene expressions. The NGS gene expression dataset of liver cancer was obtained from TCGA database. The same dataset contained early-stage and late-stage liver cancer and noncancer samples. We only used data derived from nonprocessed primary biopsies to avoid discrepancies in gene expressions that are intrinsic to cell culture and fixation. Therefore, the dataset utilized contained primary tumor samples of both stages from patients and adjacent nontumor tissue samples from the same cancer patients, which were considered to be control samples. As shown in [Table 1](#tab1){ref-type="table"}, 19 early-stage (stages I and II) and 18 late-stage (stages III and IV) liver HCC tumors and 24 adjacent normal tissue pairs were collected for further analysis. To describe the extent of a patient\'s cancer, the cancers were classified into four stages according to their degree of invasion and migration using the TNM staging system, as defined by the American Joint Committee on Cancer (AJCC) and the International Union against Cancer (UICC). We then divided the cancer samples into two groups. In general, stages I and II described early-stage cancers that have higher curability rates with medical treatment, while stages III and IV described late stages. We also combined the early and late stages for a total stage. However, there were no corresponding noncancer samples in the surrounding area for each stage, and we had only one group of surrounding noncancer samples ([Table 1](#tab1){ref-type="table"}). The reason why we had to take this step was that NGS samples are harder (and much more expensive) to obtain than microarray data, and the number of samples was small, which may have caused overfitting in the parameter estimation process of our model. So we used the total stage to identify a model to avoid overfitting. We built the CPPIN and NPPIN for early-stage, late-stage, and total-stage liver cancer in this study. We obtained 19 and 18 samples for the early-stage and late-stage liver cancer, respectively, and 24 noncancer samples. Prior to further analysis, the gene expression value, *h* ~*ij*~, was normalized to *z*-transformed scores, *g* ~*ij*~, for each gene, *i*, and then the resulting normalized expression value had a mean *μ* ~*i*~ = 0 and a standard deviation *σ* ~*i*~ = 1 for sample *j* \[[@B30], [@B31]\].

PPI data for*Homo sapiens* were extracted from the Biological General Repository for Interaction Database (BioGRID, downloaded in October 2012). The BioGRID is an open-access archive of genetic and protein interactions that are curated from the primary biomedical literature of all major model organisms. As of September 2012, BioGRID housed more than 500,000 manually annotated interactions from more than 30 model organisms \[[@B32]\]. The above two databases were mined for liver cancer and noncancer PPINs using their corresponding microarray data. These early-stage and late-stage liver cancer and noncancer PPINs were then compared to obtain network markers.

2.3. Selection of a Protein Pool and Identification of PPINs for Cancerous and Noncancerous Cells {#sec2.3}
-------------------------------------------------------------------------------------------------

To integrate gene expressions with PPI data so we could construct the corresponding CPPINs and NPPINs, we set up a protein pool containing differentially expressed proteins. Gene expression values were reasonably assumed to correlate with protein expression levels. We used a one-way analysis of variance (ANOVA) to analyze the expression of each protein and selected proteins with differential expression levels. This method allowed determination of significant differences between cancer and noncancer datasets. The null hypothesis (Ho) was based on the assumption that mean protein expression levels of cancer and noncancer sets were the same. A Bonferroni adjustment \[[@B33]\], a type of multiple testing, was used to detect and correct proteins with a discrepancy. Proteins with a *p* value of \<0.01 were included in the protein pool. However, any proteins in the protein pool which did not have PPI information were eliminated. In addition, proteins that were not already in the protein pool were included if their PPI information determined that they were closely associated with proteins already in the pool. As a result, the protein pool contained proteins that had certain differences in expression levels and proteins that had close relationships with the aforementioned proteins.

On the strength of the significant pool and PPI information, candidate PPINs for early-stage and late-stage liver cancer were constructed for liver cancer and noncancer tissues by linking proteins that interacted with each other. In other words, proteins that had PPI information through the pool were linked together, resulting in candidate PPINs.

As the candidate PPIN included all possible PPIs under various environments, different organisms, and experimental conditions, the candidate PPIN needed to be further confirmed by microarray data to identify appropriate PPIs according to the biological processes that are relevant to cancer. To remove false-positive PPIs from each candidate PPIN for different biological conditions, we used both a PPI model identification scheme and a model order detection method to prune each candidate PPIN using the corresponding microarray data to approach the actual PPIN. Here, the PPIs of a target protein *i* in the candidate PPIN can be depicted by the following protein association model:$$\begin{matrix}
{x_{i}\left\lbrack { n} \right\rbrack = {\sum\limits_{j = 1}^{M_{i}}{\alpha_{ij}x_{j}\left\lbrack { n} \right\rbrack + \omega_{i}\left\lbrack { n} \right\rbrack}},} \\
\end{matrix}$$where *x* ~*i*~\[*n*\] represents the expression level of the target protein *i* for sample *n*; *x* ~*j*~\[*n*\] represents the expression level of the *j*th protein interacting with target protein *i* for sample *n*; *α* ~*ij*~ denotes the association interaction ability between the target protein *i* and its *j*th interactive protein; *M* ~*i*~ represents the number of proteins interacting with the target protein *i*; and *ω* ~*i*~\[*n*\] represents the stochastic noise due to other factors or model uncertainty. The biological meaning of ([1](#EEq1){ref-type="disp-formula"}) is that expression levels of target protein *i* are associated with expression levels of proteins that interact with it. Consequently, a protein association (interaction) model for each protein in the protein pool can be built using ([1](#EEq1){ref-type="disp-formula"}).

After constructing ([1](#EEq1){ref-type="disp-formula"}) for the PPI model of each protein in the candidate PPIN, we used the maximum-likelihood estimation method \[[@B34]\] to identify association parameters in ([1](#EEq1){ref-type="disp-formula"}) using microarray data as follows (see Supplementary Materials S.1 available online at <http://dx.doi.org/10.1155/2015/391475>):$$\begin{matrix}
{x_{i}\left( { n} \right) = {\sum\limits_{j = 1}^{M_{i}}{{\hat{\alpha}}_{ij}x_{j}\left( { n} \right) + w_{i}\left( { n} \right)}},} \\
\end{matrix}$$where ${\hat{\alpha}}_{ij}$ was identified using microarray data in accordance with the maximum-likelihood estimation method.

Once the association parameters for all proteins in the candidate PPIN were identified for each protein, significant protein associations were determined using the interaction model order detection method based on estimated association abilities, that is, to detect the interaction number *M* ~*i*~ in ([2](#EEq2){ref-type="disp-formula"}). The Akaike information criterion (AIC) \[[@B34]\] and Student\'s *t*-test \[[@B35]\] were used for both model order selection and significance determination of protein associations in ${\hat{\alpha}}_{ij}$ (see Supplementary Materials S.2).

2.4. Determination of Significant Proteins and Their Network Structures in the Carcinogenesis of Liver Cancer {#sec2.4}
-------------------------------------------------------------------------------------------------------------

After the interaction number *M* ~*i*~′ was determined using the AIC order detection and Student\'s *t*-test, spurious false-positive PPIs, ${\hat{\alpha}}_{ij}$, in ([2](#EEq2){ref-type="disp-formula"}) were pruned away, and only significant PPIs that remained were refined as follows:$$\begin{matrix}
{x_{i}\left( { n} \right) = {\sum\limits_{j = 1}^{M_{i}^{\prime}}{{\hat{\alpha}}_{ij}x_{j}\left( { n} \right)}} + w_{i}^{\prime}\left( { n} \right),\mspace{1800mu} i = 1,2,\ldots,M} \\
\end{matrix}$$where *M* ~*i*~′ ≤ *M* ~*i*~ denotes the number of significant PPIs of the PPIN, with the target protein *i*. In other words, a number of *M* ~*i*~ − *M* ~*i*~′\'s (or false positives) were pruned from the PPIs of target protein *i*. One protein by one protein (i.e., *i* = 1,2,..., *M* for all proteins in the refined PPIN in ([3](#EEq3){ref-type="disp-formula"})) resulted in the following refined PPIN:$$\begin{matrix}
{X\left( { n} \right)AX\left( { n} \right) + w\left( { n} \right)} \\
 \\
{X\left( { n} \right) = \begin{bmatrix}
{x_{1}\left\lbrack n \right\rbrack} \\
{x_{2}\left\lbrack n \right\rbrack} \\
 \vdots \\
{x_{M}\left\lbrack n \right\rbrack} \\
\end{bmatrix},} \\
{A = \begin{bmatrix}
{\hat{\alpha}}_{11} & \ldots & {\hat{\alpha}}_{1M} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1} & \cdots & {\hat{\alpha}}_{MM} \\
\end{bmatrix},} \\
{w\left( { n} \right) = \begin{bmatrix}
{w_{1}^{\prime}\left\lbrack n \right\rbrack} \\
{w_{2}^{\prime}\left\lbrack n \right\rbrack} \\
 \vdots \\
{w_{M}^{\prime}\left\lbrack n \right\rbrack} \\
\end{bmatrix},} \\
\end{matrix}$$where the interaction matrix *A* denotes the PPIs.

If there was no PPI between proteins *i* and *j* or it was pruned away by the AIC order detection due to insignificance in the refined PPIN, then ${\hat{\alpha}}_{ij} = 0$. In general, ${\hat{\alpha}}_{ij} = {\hat{\alpha}}_{ji}$, but if this was not the case, the larger one was chosen as ${\hat{\alpha}}_{ij} = {\hat{\alpha}}_{ji}$ to avoid the situation where ${\hat{\alpha}}_{ij} \neq {\hat{\alpha}}_{ji}$. The above PPIN construction method was used to construct refined PPINs for each stage of liver cancer (early and late) and noncancer cells. The interaction matrices *A* of the refined PPINs in ([4](#EEq4){ref-type="disp-formula"}) for cancer and noncancer cells of both the early and late stages of liver cancer were constructed, respectively, as follows:$$\begin{matrix}
{A_{C}^{k}\begin{bmatrix}
{\hat{\alpha}}_{11,C}^{k} & \ldots & {\hat{\alpha}}_{1M,C}^{k} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1,C}^{k} & \cdots & {\hat{\alpha}}_{MM,C}^{k} \\
\end{bmatrix},} \\
 \\
{A_{N}^{k} = \begin{bmatrix}
{\hat{\alpha}}_{11,N}^{k} & \ldots & {\hat{\alpha}}_{1M,N}^{k} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1,N}^{k} & \cdots & {\hat{\alpha}}_{MM,N}^{k} \\
\end{bmatrix},} \\
\end{matrix}$$where *k* is the early-stage and late-stage liver cancer; *A* ~*C*~ ^*k*^ and *A* ~*N*~ ^*k*^ denote interaction matrices of the refined PPIN of the *k*th stage of liver cancer and noncancer, respectively; and *M* is the number of proteins in the refined PPIN. Therefore, the protein association model for CPPIN and NPPIN in the *k*th-stage liver cancer and noncancer samples can be represented by the following equations according to ([4](#EEq4){ref-type="disp-formula"}) and ([5](#EEq5){ref-type="disp-formula"}):$$\begin{matrix}
{x_{C}^{k}\left( { n} \right)A_{C}^{k}x_{C}\left( { n} \right) + w_{C}^{k}\left( { n} \right)} \\
 \\
{x_{N}^{k}\left( { n} \right) = A_{N}^{k}x_{N}\left( { n} \right) + w_{N}^{k}\left( { n} \right),} \\
\end{matrix}$$where *k* is early-stage and late-stage liver cancer, *x* ~*C*~ ^*k*^(*n*) = \[*x* ~1*C*~ ^*k*^  *x* ~2*C*~ ^*k*^ ⋯ *x* ~*MC*~ ^*k*^\]^*T*^ and *x* ~*N*~ ^*k*^(*n*) = \[*x* ~1*N*~ ^*k*^  *x* ~2*N*~ ^*k*^ ⋯ *x* ~*MN*~ ^*k*^\]^*T*^ denote vectors of expression levels, and *w* ~*C*~ ^*K*^(*n*) and *w* ~*N*~ ^*K*^(*n*) indicate noise vectors of the PPINs in the *k*th stage liver cancer and noncancer cells, respectively.

The different matrix *A* ~*C*~ ^*k*^ − *A* ~*N*~ ^*k*^ of the differential PPI network between CPPIN and NPPIN in the *k*th stage liver cancer is defined as follows:$$\begin{matrix}
{D^{k}\begin{bmatrix}
d_{11}^{k} & \ldots & d_{1M}^{k} \\
 \vdots & \ddots & \vdots \\
d_{M1}^{k} & \cdots & d_{MM}^{k} \\
\end{bmatrix}} \\
{= \begin{bmatrix}
{{{\hat{\alpha}}^{k}}_{11,C} - {{\hat{\alpha}}^{k}}_{11,N}} & \ldots & {{{\hat{\alpha}}^{k}}_{1M,C} - {{\hat{\alpha}}^{k}}_{1M,N}} \\
 \vdots & \ddots & \vdots \\
{{{\hat{\alpha}}^{k}}_{M1,C} - {{\hat{\alpha}}^{k}}_{M1,N}} & \cdots & {{\hat{\alpha}}_{MM,C}^{k} - {\hat{\alpha}}_{MM,N}^{k}} \\
\end{bmatrix},} \\
\end{matrix}$$where *k* is early-stage and late-stage liver cancer, *d* ~*ij*~ ^*k*^ denotes the protein association ability difference between CPPIN and NPPIN in the *k*th-stage liver cancer, and matrix *D* ^*k*^ indicates the difference in network structures between CPPIN and NPPIN in the *k*th-stage liver cancer. In order to investigate carcinogenesis from the difference matrix, *D* ^*k*^, between CPPIN and NPPIN of the *k*th-stage liver cancer in ([7](#EEq7){ref-type="disp-formula"}), a score, which we called the carcinogenesis relevance value (CRV), was presented to quantify the correlation of each protein in *D* ^*k*^ with the significance of carcinogenesis as follows \[[@B30]\]:$$\begin{matrix}
{CRV^{k} = \begin{bmatrix}
{CRV_{1}^{k}} \\
 \vdots \\
{CRV_{i}^{k}} \\
 \vdots \\
{CRV_{M}^{k}} \\
\end{bmatrix},} \\
\end{matrix}$$where CRV~*i*~ ^*k*^ = ∑~*j*=1~ ^*M*^\|*d* ~*ij*~ ^*k*^\| and *k* is early-stage and late-stage liver cancer.

The CRV~*i*~ ^*k*^ in ([8](#EEq8){ref-type="disp-formula"}) quantifies the differential extent of protein associations of the *i*th protein (the absolute sum of the *i*th row of *D* ^*k*^ in ([7](#EEq7){ref-type="disp-formula"})) and the CRV^*k*^ can differentiate CPPIN from NPPIN in *k*th-stage liver cancer. In other words, the CRV~*i*~ ^*k*^ in ([8](#EEq8){ref-type="disp-formula"}) represents the network structure difference of the *i*th protein between cancer and noncancer networks in the *k*th-stage liver cancer.

In order to investigate what proteins are more likely involved in *k*th-stage liver cancer, we needed to calculate the corresponding empirical *p* value to determine the statistical significance of the CRV~*i*~ ^*k*^. To determine the observed *p* value of each CRV~*i*~ ^*k*^, we repeatedly permuted the network structure of the candidate PPIN of the *k*th-stage liver cancer as a random network of *k*th-stage liver cancer. Each protein in the random network of the *k*th-stage liver cancer had its own CRV to generate a distribution of CRV~*i*~ ^*k*^ for *k* = early-stage and late-stage liver cancer. Although the network structure was randomly disarranged, linkages of each protein were maintained. In other words, proteins with which a particular protein interacted were permuted without changing the total number of protein interactions. This procedure was repeated 10^5^ times, and the corresponding *p* value was calculated as the fraction of the random network structure in which the CRV~*i*~ ^*k*^ was at least as large as the CRV of the real network structure. According to distributions of the CRV~*i*~ ^*k*^ of the random networks, the CRV~*i*~ ^*k*^ in ([8](#EEq8){ref-type="disp-formula"}) with a *p* value of ≤0.01 was regarded as a significant CRV, and the corresponding protein was determined to be a significant protein in the carcinogenesis of the *k*th-stage liver cancer: a protein with a *p* value of \>0.01 was removed from the list of significant proteins in carcinogenesis (in other words, if the *p* value of CRV~*i*~ ^*k*^ was \>0.01, then the *i*th protein was removed from the CRV~*i*~ ^*k*^ in ([8](#EEq8){ref-type="disp-formula"}), and the remainder in the CRV^*k*^ with *p* values of CRVs of \<0.01 was considered significant proteins of the *k*th-stage liver cancer).

Based on *p* values of the CRVs for all proteins (*i* = 1,2,..., *M*) and the two stages of liver cancer (*k* = early-stage and late-stage liver cancer), we generated two lists of significant proteins for each of the two stages according to the CRV and a statistical assessment of each significant protein in the CRV^*k*^ in ([8](#EEq8){ref-type="disp-formula"}). We found 152 significant proteins in the early-stage liver cancer and 50 significant proteins in the late-stage liver cancer. These proteins showed significant changes between the CPPIN and NPPIN in the carcinogenic process according to their corresponding stage of cancer, and we suspected that these changes might play important roles in the carcinogenesis process of liver cancer. These findings warrant further investigation.

Intersections of these significant proteins in the early and late stages of liver cancer and their PPIs are known as the core network markers appearing in all stages of liver cancer. In contrast, unique significant proteins and their PPIs in each stage of liver cancer are known as specific network markers for each stage of cancer. We found 18 significant proteins that could be classified as core network markers over the entire carcinogenesis process of liver cancer. We also found 134 significant proteins as specific network markers of early-stage liver cancer and 32 significant proteins as specific network markers of late-stage liver cancer.

2.5. Pathway Analysis {#sec2.5}
---------------------

Much valuable cellular information can be found using known pathways, which are useful for describing most "normal" biological phenomena. All of these known pathways are the result of repeated testing and verification, and the entire pathway network has defined most links. Therefore, the proteins we identified to be significant in the above network markers were mapped onto known pathway networks (e.g., the Kyoto Encyclopedia of Genes and Genomes (KEGG) and PANTHER pathways) to investigate significant pathways with network markers and explore relationships between these pathways and the carcinogenesis of liver cancer. This approach supports the view that systems biology can help identify significant network biomarkers in both normal and cancerous pathways and their roles in the pathogenesis of cancer.

Together with comprehensive pathway databases such as the KEGG, we used a series of bioinformatics pathway analytical tools to identify biologically relevant pathway networks \[[@B36]\]. The KEGG includes manually curated biological pathways that cover three main categories: systems information (e.g., human diseases and drugs), genomics information (e.g., gene catalogs and sequence similarities), and chemical information (e.g., metabolites and biochemical reactions). At present, the KEGG contains 134,511 distinct pathways generated from 391 original reference pathways \[[@B37]\]. Therefore, to investigate pathways involved in carcinogenesis, the bioinformatics database, DAVID \[[@B38], [@B39]\], which generates automatic outputs of the results from a KEGG pathway analysis \[[@B38]\], was used for the pathway analysis of significant proteins identified as network markers to determine their roles in the pathogenesis of early- and late-stage liver cancer. Our methodology did not include a pathway analysis or gene set enrichment analysis (GSEA). To complete our research results, we used NOA software for the pathway analysis and GSEA of biological processes, cellular components, and molecular functions \[[@B41], [@B42]\].

2.6. Explore the Evolution of Network Biomarkers in the Liver Carcinogenesis via PPI Network through NGS Data {#sec2.6}
-------------------------------------------------------------------------------------------------------------

Our cancer PPI model was constructed from the differential expression of cancer and noncancer microarray data and data mining of PPI information from the BioGRID database. So, the early-stage and late-stage liver CPPINs and NPPINs were the results of our systems biology model using the original NGS data and PPI databases. There were two key factors that affected our final results.

*(i) The Effect of Different Original PPI Databases*. We know that PPI databases, such as the BioGRID and MIPS, are constructed from putative samples and validated by wet-lab experiments. Due to advances in many high-throughput experimental skills, the original PPI databases have evolved over time. The newly updated original PPI databases are the second factor to affect the final results.

*(ii) The Effect of the Systems Biology Model*. Microarray data, PPI databases, and the PPI interaction model in ([1](#EEq1){ref-type="disp-formula"}) were employed to construct PPI networks of normal and cancer cells by the maximum-likelihood parameter estimation method (see Supplementary Materials S.1). The AIC system order detection method (Supplementary Materials S.2) was used to prune false-positive PPIs to obtain actual PPI networks of normal and cancer cells; that is, we used the so-called reverse engineering method to construct PPI networks of normal and cancer cells. Then, the DPPIN between the CPPIN and NPPIN was obtained in ([7](#EEq7){ref-type="disp-formula"}) to investigate PPI variations of each protein in the DPPIN due to carcinogenesis. Finally, the CRV based on PPI variations was also proposed to evaluate the significance of carcinogenesis for each protein of the DPPIN. Proteins with a significant CRV (*p* \< 0.01) were considered significant proteins of the cancer. Significant proteins in [Table 3](#tab3){ref-type="table"} were these significant proteins of early-stage and late-stage liver cancer, and these proteins and their PPIs were used to construct the PPI network in [Figure 2](#fig2){ref-type="fig"}. Finally, from early-stage and late-stage liver cancer network markers, we investigated mechanisms of the carcinogenesis process with the help of databases (e.g., the GO database and the DAVID and KEGG pathway databases) to find multiple network targets for cancer therapy. Unlike conventional theoretical methods which always give a single mathematical model for a cancer network for a more-detailed theoretical analysis, this study introduced a systems biology approach to cancer network markers based on actual NGS data through so-called reverse engineering, a systems statistical method, and a data mining method in combination with large databases. These are the novelty and significance of our study. Although we described the novelty of our systems biology model, we have validated our results by a literature survey of research. In the future, our results can be validated by other researchers\' wet-lab experiments, and we will repeatedly modify our mathematical system model. This is the third key factor that affected our results. Although not directly, it also influenced the protein interaction network.

We also know that biosystems evolve with time. It is obvious that early-stage and late-stage patients have very different symptoms; these are key features we used to classify early-stage and late-stage liver cancer. Since liver cancer patients in the two stages have very different symptoms, the NGS data of these two stages of patients should undoubtedly greatly differ. As described above, protein expressions from NGS data are one of the key factors of our systems biology model producing the final CPPINs and NPPINs, and the CPPINs and NPPINs gave the final network biomarkers from our systems biology model. So, the most important thing for evolution of network biomarkers is evolution of the NGS data in both stages of liver cancer, which is inherent in the exhibition of cancer-related genes due to DNA mutations in the carcinogenesis process.

3. Results and Discussion {#sec3}
=========================

3.1. Evolution of Network Biomarkers in Early-Stage and Late-Stage Liver Cancer {#sec3.1}
-------------------------------------------------------------------------------

We built the DPPIN to examine the early, late, and total stages of liver cancer ([Figure 2](#fig2){ref-type="fig"}). CRVs of each protein in the three networks were calculated. This figure shows more-detailed information than just the CRVs; that is, it shows the changes of edges and nodes at different stages of the network. By screening using *p* values of CRVs, we found significant proteins of network markers for these three stages of liver cancer. Similar to our previous experience with bladder cancer \[[@B16]\], we wanted to reveal the carcinogenesis mechanisms of liver cancer in the early and late stages. Because we combined the early stage (stages I and II) and late stage (stages III and IV) into a total stage (stages I\~IV), it is not surprising that most of the pathways associated with either the early or late stage overlapped those of the total stage. We had to perform this step because NGS samples are more difficult (and much more expensive) to obtain than microarray data; that is, there were few samples. This shortage may have caused overfitting in the parameter estimation process of our model in ([2](#EEq2){ref-type="disp-formula"}). So we used the total stage again to build a model to avoid overfitting. To summarize, we built a model using early, late, and total stages. Numbers of samples in these three stages were 19, 18, and 37, respectively (37 being the sum of 19 and 18). The reason for using the total stage is that 19 and 18 are small numbers of samples, and there was the chance that overfitting may have occurred. So we used the sum of the early and late stages (37) to see the entire picture between cancer and noncancer tissues.

3.2. Network Markers of Early, Late, and Total (Early Plus Late Stages) Stages of Liver Cancer {#sec3.2}
----------------------------------------------------------------------------------------------

After *p* value (0.01) screening, we found that there were 43, 80, and 74 significant proteins for the early, late, and total stages of liver cancer, respectively. In addition, their corresponding CRVs ranged 6.0\~46.5, 6.1\~34.1 and 6.5\~81.5, respectively. These significant proteins and their PPIs were used to construct network markers for the early, late, and total stages of liver cancer. The intersection network of markers of the early and late stages was a core feature that contained 27 significant proteins associated with carcinogenesis. We list the 27 significant proteins and their corresponding CRVs and *p* values in both stages of liver cancer in [Table 2](#tab2){ref-type="table"}. In the second step, we separately list the top 20 significant proteins in the early and late stages of liver cancer in [Table 3](#tab3){ref-type="table"}. The full list of the 43, 80, and 74 significant proteins for these three stages of liver cancer is given in Supplementary Tables S3. [Table 4](#tab4){ref-type="table"} shows the top 30 proteins of the total stage. [Table 5](#tab5){ref-type="table"} shows interactions with our previous results using microarray data.

3.3. Pathway Analysis of the Total Stage of Liver Cancer {#sec3.3}
--------------------------------------------------------

We first analyzed the pathway of the total stage of liver cancer using the David database. As stated above, the key point of this research was to find evolutionary mechanisms of liver cancer from the early and late stages, but the number of samples of NGS data was small, so we had to combine the early and late stages to see the overall picture of the liver cancer network. The five key pathways we were interested in, which were selected by these 74 key proteins, are listed as follows: (1) 14 proteins in hsa04110 were associated with the cell cycle ([Figure 3(a)](#fig3){ref-type="fig"}), (2) seven proteins in hsa04114 were associated with oocyte meiosis ([Figure 3(b)](#fig3){ref-type="fig"}), (3) five proteins in hsa03030 were associated with DNA replication ([Figure 3(c)](#fig3){ref-type="fig"}), (4) 10 proteins in hsa05200 were associated with cancer pathways ([Figure 3(d)](#fig3){ref-type="fig"}), and (5) four proteins in hsa04115 were associated with the p53 signaling pathway ([Figure 3(e)](#fig3){ref-type="fig"}). We only focused on those pathways related to liver cancer and eliminated unrelated ones, such as prostate cancer, glioma (brain cancer) pathway, and small cell lung cancer pathway ([Table 6](#tab6){ref-type="table"}).

*(1) Cell Cycle*. An abnormal cell cycle is highly related to cancer mechanisms. We described this in our previous study \[[@B15], [@B16]\]. More clues and mechanisms were revealed in this study, so we have to repeat and highlight the previous results while adding the new results. Dysregulation of the cell cycle governs deviant cell proliferation in cancer. Loss of the ability to control cell cycle checkpoints induces abnormal genetic instability. It is well known that the cell cycle is composed of two consecutive periods, characterized by DNA replication, and of sequential differential and segregation of replicated chromosomes into two separate daughter cells. This may be due to activation of tumorigenic mutations, which were recognized in various tumors at different levels in mitogenic signal transduction pathways: (1) ligands and receptors (receptor mutations of HER2/neu \[ErB2\] or amplification of the HER2 gene), (2) downstream signal transduction networks (Raf/Ras/MAPK or PI3K-AKT-mTOR), and (3) regulatory genes of the cell cycle (cyclin D1/CDK4, CDK6, and cyclin E/CDK2) \[[@B43]\]. There are many reported discussions regarding cell cycle regulators and checkpoint functions involved in HCC \[[@B44]--[@B47]\]. Herein, 14 of the total stage network markers identified were involved in the cell cycle pathway. In this case, we found that five of these 14 markers were related to the DNA replication pathway. This shows that the cell cycle and DNA replication are highly related to liver cancer at the total stage.

Because the cell cycle is so crucial to cancer, we list other pathways given by BioCarta (Figures [3(e)](#fig3){ref-type="fig"} and [3(f)](#fig3){ref-type="fig"}). The former shows that these key proteins are related to the G~1~/S checkpoint, while the later shows that they are related to regulation of p27 phosphorylation during cell cycle progression.

Dituri et al. showed that changes in the cell cycle checkpoint frequently occur during HCC. They identified different pathways from us and showed that the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of the rapamycin (mTOR) pathway is the key pathway for HCC. They used the human PLC/PRF/5, Hep3B, HepG2, HLE, and HLF HCC cell lines and a normal human hepatocyte cell line. Although they and our group did not identify the same targets, the key point is that an abnormal cell cycle is a complex mechanism. Their scope covered the G~0~-G~1~, G~2~-M, and G~1~-S phases \[[@B46]\]. Our future work will try to link our network makers with mechanisms discovered by other groups.

Furuta et al. showed that micro- (mi)RNAs are key posttranscriptional regulators of gene expression and are usually deregulated in HCC. They identified four miRNAs, mir-101, mir-195, mir-378, and mir-497 that are always silenced in HCC. In this research, we did not include miRNAs when building the model \[[@B47]\]. We know that miRNAs play significant roles in genetic regulatory networks, and our future work will incorporate miRNAs into our model to reveal more hidden mechanisms of HCC.

*(2) Oocyte Meiosis*. We did notidentify this pathway in our previous study. Zhang et al. used network-based bioinformatics methods to identify biomarkers for HCC and identified this pathway with 19 upregulated genes with a *p* value of 0.0016 \[[@B48]\]. We identified seven genes in this pathway with a very low *p* value of 8.70*E*−05. Terret et al. claimed that mouse oocytes are a paradigm of cancer cells. They showed asymmetric division in both mitotic cells and oocytes cells, and this causes cancer cells to divide \[[@B49]\].

*(3) DNA Replication*. As we stated above, we identified five genes of the DNA replication pathway which are also involved in the cell cycle pathway. Macheret and Halazonetis claimed that DNA replication stress is a hallmark of cancer \[[@B50]\], so we have to discuss this topic in more detail here. Hanahan and Weinberg published two review papers on the topic of cancer hallmarks, and the key points are listed here. Based on their first-generation cancer hallmarks \[[@B2]\], Hanahan and Weinberg extended their work to second-generation hallmarks of cancers \[[@B3]\]. It inspired many people and stimulated many ideas on cancer targeted therapies.

*(i) Sustaining Proliferative Signaling*. Cancer cells can sustain proliferative signaling in various ways, become independent of exogenous growth signals, and so can proliferate. They also have the ability to generate growth factor ligands themselves.

*(ii) Evading Growth Suppressors*. Cancer cells can ignore signals that inhibit cell proliferation. Retinoblastoma-associated (RB) and TP53 proteins are the two main prototypes of tumor suppressors. They are also important targets of cancer therapies.

*(iii) Activating Invasion and Metastasis*. Invasion and metastasis comprise multistep processes, usually called the invasion-metastasis cascade. This cascade is related to the mechanisms of miRNAs \[[@B51], [@B52]\].

*(iv) Enabling Replicative Immortality*. Cancer cells becoming immortal is a lethal event for cancer patients. There are three important topics to this immortality: reassessing replicative senescence, delayed activation of telomerase, and new noncanonical functions of telomerases.

*(v) Inducing Angiogenesis*. Both invasion and metastasis need new-born blood vessels to supply nutrients for cancer cells.

*(vi) Resisting Cell Death*. Cancer cells have many strategies to disable apoptosis. Cancer cells becoming immortal is another lethal event for cancer patients.

When we tried to apply a systems biology approach to cancer therapy, understanding cancer hallmarks was the most important and basic step. There are many investigations of cancer systems biology based on Weinberg\'s work. Negrini et al. discussed the genomic instability characteristics of cancers and evolving hallmarks of cancer \[[@B53]\]. Hornberg et al. used the concept of complex signaling networks and increases in complexity to directly name cancers as systems biology disease \[[@B54]\]. Barillot et al. merged the six hallmarks into the following three main properties related to the proliferation, survival, and dissemination of cancers. They are the defective control of the cell cycle, defective control of cell death, and the invasiveness and metastatic potential. There are three key levels at which normal cells transform into cancer cells: mutations of DNA, transcription of DNA to RNA, and RNA translation to proteins. Hallmarks are omens and portent of cancers, and, by a pathway analysis, we can find drug targets at this stage.

Cancer is a network disease, that is, a dysregulation of the entire network. Determining how to build a cancer network is the first important task.

We have briefly reviewed and summarized the key points of Weinberg\'s theory. Now we focus on DNA replication stress, because it was identified as another hallmark of cancer. Macheret and Halazonetis claimed that the sustained proliferation hallmark can be regarded as mutations in oncogenes and tumor suppressor genes that are involved in the cell growth pathway. Mutations of TP53, ATM, or MDM2 genes can allow escaping from the apoptosis hallmark. He discussed oncogene-induced DNA replication stress and the role it plays as a cancer progression driver \[[@B50]\].

*(4) p53 Signaling Pathway*. Soussi et al. discussed a multifactorial analysis of p53 alterations in human cancers \[[@B55]\]. Ueda et al. claimed that the functional inactivation but not the structural mutation of p53 can cause liver cancer \[[@B56]\].

3.4. Pathway Analysis of Early-Stage Liver Cancer {#sec3.4}
-------------------------------------------------

Four of these five key pathways discussed in the total stage (cell cycle, DNA replication, oocyte meiosis, and p53 signaling) were also selected by both early and late stages, although the proteins involved in these pathways were not the same ([Table 7](#tab7){ref-type="table"}). We should pay more attention to the evolution from the early to late stages.

*(1) Mismatch Repair*. This is a key pathway that was only selected by the early stage (with higher *p* value of 0.09) but not the late stage ([Figure 4](#fig4){ref-type="fig"}). Fujimoto et al. sequenced the entire genome of liver cancers to identify etiological influences on mutation patterns. They discussed transcription-coupled repair and mismatch repair-deficient tumors to show that mismatch repair plays a significant role in liver cancer \[[@B57]\].

3.5. Pathway Analysis of Late-Stage Liver Cancer {#sec3.5}
------------------------------------------------

*(1) Spliceosome*. It is important that we selected the spliceosome pathway again in late-stage liver cancer ([Table 8](#tab8){ref-type="table"}), because we selected it in our previous results of late-stage bladder cancer. We review previous results of the spliceosome pathway \[[@B16]\] and then add new results here. Alternative splicing is a modification of premessenger (m)RNA transcripts in which internal noncoding regions of pre-mRNA (introns) are removed and then the remaining segments (exons) are joined ([Figure 5](#fig5){ref-type="fig"}). The formation of mature mRNA is subsequently capped at its 5′ end, polyadenylated at its 3′ end, and transported out of the nucleus to be translated into proteins in the cytoplasm. Most genes use alternative splicing to generate multiple spliced transcripts. These transcripts contain various combinations of exons resulting from different mRNA variants, and these are synthesized as protein isoforms. Exons are always around 50\~250 base pairs, whereas introns can be as long as several thousands of base pairs. For nuclear-encoded genes, splicing takes place within the nucleus simultaneously with or after transcription. Splicing is necessary for eukaryotic mRNA before it can be translated into the correct protein. The spliceosome is a dynamic intracellular macromolecular complex of multiple proteins and ribonucleoproteins (RNPs). For many eukaryotic introns, the spliceosome carries out the two main functions of alternative splicing: first, it recognizes intron-exon boundaries, and, second, it catalyzes cut-and-paste reactions that remove introns and concatenate exons. Various spliceosomal machinery complexes are formed from five RNP subunits, termed uridine- (U) rich small nuclear (sn)RNPs, that are transiently associated with more than 760 non-snRNP splicing factors (RNA helicases, SR splicing factors, etc.) \[[@B58], [@B59]\]. Each spliceosomal snRNP (U1, U2, U4, U5, and U6) consists of a U-rich snRNA complexed with a set of seven proteins known as canonical Sm core or SNRP proteins. The seven Sm proteins (B/B′, D1, D2, D3, E, F, and G) form a core ring structure that surrounds the RNA. All Sm proteins contain a conserved sequence motif in two segments (Sm1 and Sm2) that are responsible for the assembly and ordering of snRNAs. They form the Sm core of spliceosomal snRNPs \[[@B60]\] and process pre-mRNA \[[@B61]\]. Spliceosomes not only catalyze splicing by a series of reactions, but also are the main cellular machinery that guides splicing. Recently, scientists found two natural compounds that can interfere with spliceosome function that also display anticancer activity in vitro and in vivo \[[@B62], [@B63]\]. Therefore, it is thought that inhibiting the spliceosome can be a new target for anticancer drug development \[[@B64]\], and it should be validated in vivo and in vitro in the future \[[@B57]\].

Tian et al. used a phosphoproteomic analytical method on the highly metastatic HCC cell line, MHCC97-H. They reported that phosphoproteins were also found in the spliceosome pathway, and they were related to liver cancer \[[@B65]\].

*(2) Progesterone-Mediated Oocyte Maturation*. Zhang et al. also identified this pathway \[[@B48]\].

*(3) Lysine Degradation*. Huang et al. identified this pathway in liver cancer \[[@B66]\].

3.6. Comparison with Our Previous Liver Cancer Network Biomarkers Using a Microarray Analysis {#sec3.6}
---------------------------------------------------------------------------------------------

We found 15 common proteins in this study and our previous results ([Table 5](#tab5){ref-type="table"}). That tells us that the NGS is a revolutionary technology, but it can be trusted to not give totally different results from microarray data.

3.7. Comparison of Microarray and NGS Technology {#sec3.7}
------------------------------------------------

Gene expression profiling by microarray has been successful at demonstrating the patterns of mRNAs within tissues and cells. Although microarray platforms showed similar levels of concordance with the RNA-seq data, the next generation sequencing (NGS) technologies provided high sensitivity, specificity, and accuracy as compared to the microarray platforms \[[@B67]\]. Due to NGS providing a more detailed observation at the transcriptome, scientists and biologists have been eager to apply NGS for gene expression profiling. Microarrays only return results from those regions for probes which have been designed. Therefore, microarrays are only as good as the databases from which they are designed. NGS methods provide aspects of the transcriptome without a priori knowledge, allowing for the analysis and discovery of novel transcripts, noncoding RNAs, and alternative splicing. Thus, RNA sequencing methods enable the most accurate detection and quantification for transcriptome analysis.

4. Conclusions {#sec4}
==============

Liver cancer is the third most deadly cancer causing about 700,000 deaths in 2011 worldwide. It is a lethal disease like other cancers. There are three important topics in this research. The first was to compare this study with our previous research of liver cancer microarray data, because the microarray technology may someday be replaced by the NGS technology. We found the results to be good, because there were a lot of key proteins identified by both methods. The second was to reveal the carcinogenesis process from the early to late stages of liver cancer. The specific pathway of the early stage was the mismatch repair pathway, and the specific pathways of the late stage were the spliceosome pathway, lysine degradation pathway, and progesterone-mediated oocyte maturation pathway. This suggests novel directions for choosing different targeted therapeutic strategies at different stages of cancer. In particular, compared to our previous results of bladder cancer, we found that the spliceosome pathway is a significant pathway in the late stage of both liver cancer and bladder cancer. Our future work will focus greater attention on this pathway related to various cancers and consider it as a new drug target for anticancer therapies.

Supplementary Material {#supplementary-material-sec}
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###### 

Supplementary material S.1 uses the Maximum Likelihood Method to do the parameter identification of regression model in equation (1). S.2 uses the AIC and student\'s t-test to calculate the p-values of association abilities, and detect the system model order and determine the significance of the model parameters. Table S3: (a) The 43 identified significant proteins of early stage liver cancer. (b) The 80 identified significant proteins of late stage liver cancer. (c) The 74 identified significant proteins of total stage liver cancer.
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![Flowchart illustrating construction of network markers in two stages of liver cancer and the investigation of carcinogenesis mechanisms. We integrated NGS data, the GO database, and protein-protein interaction (PPI) information to construct the PPI network. These data were used for pool selection, and then the selected proteins and NGS data were used to contribute to the PPI network (PPIN) by a maximum-likelihood estimation and model order detection method, resulting in a liver cancer PPIN (CPPIN) and a noncancer PPIN (NPPIN) in the early and late stages of liver cancer. The two constructed PPINs were used to determine significant proteins of tumorigenesis by examining differences between the two PPI matrices of the two constructed PPINs. With the help of a differential PPI matrix (network) between CPPIN and NPPIN, a carcinogenesis relevance value (CRV) was computed for each protein, and significant proteins in carcinogenesis were determined based on *p* values of the CRVs of these proteins in the differential PPI matrix between CPPIN and NPPIN. These significant proteins were obtained for early and late stages of liver cancer.](BMRI2015-391475.001){#fig1}

![The constructed cancer differential protein-protein interaction networks (DPPINs) for early, late, and total stages of liver cancer. This figure shows the DPPINs with edge and node information for the early, late, and total stages of liver cancer. The DPPIN is the difference between the cancer PPIN (CPPIN) and noncancer PPIN (NPPIN). The figures were created using Cytoscape.](BMRI2015-391475.002){#fig2}

![Overview of significant pathways in network marker of total stage of liver cancer. Among KEGG pathways identified via the DAVID tool ([Table 4](#tab4){ref-type="table"}) showing significant associations with specific proteins of the early stage of liver cancer, these molecular pathways had *p* values of ≤0.05. This indicates that these pathways play important roles in the carcinogenesis mechanism in the early stage of liver cancer. The network markers of the early stage of liver cancer highlighted by stars show potentially targets in the pathways. Due to the different naming systems, the same proteins in these tables and in the text are labeled with different names.](BMRI2015-391475.003){#fig3}

![Overview of significant pathways of network markers of early-stage liver cancer. KEGG pathways accessed using the DAVID tool ([Table 7](#tab7){ref-type="table"}) show significant associations with specific proteins in the early stage of liver cancer; these molecular pathways are labeled with *p* values of ≤0.05. These pathways were shown to play important roles in the carcinogenesis mechanism in the early stage of liver cancer. Network markers of the early stage of liver cancer as highlighted by stars show potential targets in the pathways. Due to different naming systems, the same proteins in the tables and text have different names. The proteins in the early-stage liver cancer network marker are enriched in "hsa03040:Mismatch repair" (Rank 9 in [Table 7](#tab7){ref-type="table"}).](BMRI2015-391475.004){#fig4}

![Overview of significant pathways of network markers of late-stage liver cancer. KEGG pathways identified using the DAVID tool ([Table 8](#tab8){ref-type="table"}) show significant associations with specific proteins in the late stage of liver cancer; these molecular pathways are labeled with *p* values of ≤0.05. These pathways were shown to play important roles in the carcinogenesis mechanism of the early stage of liver cancer. Proteins in network markers of the early stage of liver cancer as highlighted by stars are potential targets in the pathways. Due to different naming systems, the same proteins in the tables and in the text have different names. The proteins in the total stage liver cancer network marker are enriched in "hsa03040:Spliceosome" (Rank 5 in [Table 8](#tab8){ref-type="table"}).](BMRI2015-391475.005){#fig5}

###### 

Descriptive information on datasets extracted from the TCGA database used in this study. Cases are grouped by the type of cancer, and surrounding normal tissues came from human patients in the early or late stage of liver cancer.

  ----------------------------------------------------------------------------------------------------------------
  Cancer type    TCGA dataset number   Early stage sample\#   Late stage sample\#   Normal sample\#   Platform
  -------------- --------------------- ---------------------- --------------------- ----------------- ------------
  Liver cancer   Batch100\             19                     18                    24                Illumina\
                 of LIHC                                                                              HiSeq 2000

  ----------------------------------------------------------------------------------------------------------------

###### 

The 27 identified significant proteins of core network marker in both early-stage and late-stage liver cancer (intersection).

  Common network marker of early-stage and late-stage liver cancer                                     
  ------------------------------------------------------------------ ------- --------- ------- ------- -------
  APP                                                                46.52   0.00001   13724   14041   −0.03
  APP                                                                13.87   0.00066   15083   14041   0.1
  ELAVL1                                                             22.99   0.00033   1725    1319    0.39
  ELAVL1                                                             29.69   0.00003   1791    1319    0.44
  KRTAP10-5                                                          14.73   0.00098   1       1       0.04
  KRTAP10-5                                                          20.54   0.00022   1       1       0.06
  H2AFX                                                              14.08   0.00105   608     271     1.17
  H2AFX                                                              15.43   0.00053   806     271     1.58
  CDK1                                                               13.69   0.00108   335     34      3.32
  CDK1                                                               10.31   0.00119   596     34      4.15
  ESR1                                                               12.81   0.00119   228     1537    −2.76
  ESR1                                                               34.1    0.00000   245     1537    −2.65
  EZH2                                                               12.22   0.00127   310     49      2.66
  EZH2                                                               19.05   0.00027   394     49      3
  CEP250                                                             12.05   0.00130   716     268     1.42
  CEP250                                                             16.12   0.00045   627     268     1.23
  AURKB                                                              11.41   0.00138   141     14      3.35
  AURKB                                                              7.68    0.00289   199     14      3.85
  CDC20                                                              10.89   0.00152   359     20      4.17
  CDC20                                                              8.94    0.00168   688     20      5.11
  E2F1                                                               10.54   0.00158   476     43      3.46
  E2F1                                                               8.85    0.00174   673     43      3.95
  OTX1                                                               10.29   0.00166   31      2       4.27
  OTX1                                                               6.25    0.00811   26      2       4.02
  SUMO1                                                              9.86    0.00181   2422    2982    −0.3
  SUMO1                                                              8.63    0.00188   2624    2982    −0.18
  MCM4                                                               9.76    0.00186   1308    336     1.96
  MCM4                                                               6.76    0.00535   1327    336     1.98
  HGS                                                                7.96    0.00312   2504    1167    1.1
  HGS                                                                13.9    0.00066   2441    1167    1.06
  KPNA2                                                              7.86    0.00323   1927    689     1.48
  KPNA2                                                              10.43   0.00116   2533    689     1.88
  UBC                                                                7.85    0.00323   34388   35490   −0.05
  UBC                                                                6.63    0.00591   36931   35490   0.06
  SPRY2                                                              7.5     0.00376   409     989     −1.27
  SPRY2                                                              7.17    0.00399   328     989     −1.59
  TOPBP1                                                             7.33    0.00406   799     346     1.21
  TOPBP1                                                             6.45    0.00698   875     346     1.34
  SIRT7                                                              7.11    0.00456   442     225     0.98
  SIRT7                                                              24      0.00012   456     225     1.02
  WHSC1                                                              6.67    0.00590   1217    447     1.44
  WHSC1                                                              12.06   0.00086   1369    447     1.61
  MCM2                                                               6.45    0.00666   1097    174     2.66
  MCM2                                                               8.48    0.00200   1351    174     2.96
  AURKA                                                              6.4     0.00685   570     86      2.73
  AURKA                                                              9.25    0.00154   516     86      2.58
  COPS5                                                              6.39    0.00691   1506    1184    0.35
  COPS5                                                              10      0.00128   1708    1184    0.53
  PCNA                                                               6.29    0.00749   1652    904     0.87
  PCNA                                                               15.95   0.00046   2290    904     1.34
  BUB1B                                                              6.27    0.00762   179     12      3.89
  BUB1B                                                              7.47    0.00327   320     12      4.73
  DNMT1                                                              6.02    0.00920   1376    455     1.6
  DNMT1                                                              10.63   0.00110   1383    455     1.6

There are two rows with same proteins name while the upper row represents the early stage liver cancer and the lower raw represents the late stage liver cancer.

AvgExp means average expression.

log~2~⁡FC means log~2~⁡ fold change.

###### 

Top 20 proteins of early-stage and late-stage liver cancer.

  Protein                                       CRV     *p* value      Case_AvgExp   Control_AvgExp   log~2~⁡FC
  --------------------------------------------- ------- -------------- ------------- ---------------- -----------
  Top 20 proteins of early-stage liver cancer                                                         
  APP                                           46.52   6.09*E* − 06   13724         14041            −0.03
  KRTAP4-12                                     33.47   6.09*E* − 05   1             1                −0.17
  ELAVL1                                        22.99   0.000329       1725          1319             0.39
  KRTAP10-1                                     17.17   0.000756       1             1                0.04
  KRTAP10-5                                     14.73   0.000981       1             1                0.04
  H2AFX                                         14.08   0.001048       608           271              1.17
  CDK1                                          13.69   0.001079       335           34               3.32
  PRKDC                                         12.91   0.001176       4011          1684             1.25
  CUL3                                          12.83   0.001188       1376          1606             −0.22
  ESR1                                          12.81   0.001194       228           1537             −2.76
  EZH2                                          12.22   0.001274       310           49               2.66
  CEP250                                        12.05   0.001298       716           268              1.42
  AURKB                                         11.41   0.001383       141           14               3.35
  CDC20                                         10.89   0.001523       359           20               4.17
  E2F1                                          10.54   0.001584       476           43               3.46
  OTX1                                          10.29   0.001664       31            2                4.27
  C19orf66                                      10.2    0.001688       1551          3166             −1.03
  SUMO1                                         9.86    0.00181        2422          2982             −0.3
  MCM4                                          9.76    0.001859       1308          336              1.96
  GRB2                                          9.19    0.0022         3572          2608             0.45
                                                                                                      
  Top 20 proteins of late stage liver cancer                                                          
  ESR1                                          34.1    4.22*E* − 06   245           1537             −2.65
  ELAVL1                                        29.69   2.53*E* − 05   1791          1319             0.44
  UBD                                           28.54   3.38*E* − 05   20926         1781             3.55
  YWHAZ                                         27.31   4.22*E* − 05   13323         6408             1.06
  SIRT7                                         24      0.000122       456           225              1.02
  HDAC5                                         22.07   0.000152       1696          840              1.01
  KRTAP10-5                                     20.54   0.000224       1             1                0.06
  EZH2                                          19.05   0.00027        394           49               3
  ILF2                                          18.86   0.000283       4111          1737             1.24
  CEP250                                        16.12   0.000452       627           268              1.23
  PCNA                                          15.95   0.00046        2290          904              1.34
  SUMO2                                         15.77   0.00049        3305          2112             0.65
  H2AFX                                         15.43   0.000532       806           271              1.58
  HSP90AB1                                      14.43   0.0006         30949         14629            1.08
  HGS                                           13.9    0.000659       2441          1167             1.06
  APP                                           13.87   0.000659       15083         14041            0.1
  WHSC1                                         12.06   0.000861       1369          447              1.61
  SETDB1                                        11.7    0.000912       1203          497              1.28
  TRAF2                                         11.45   0.000938       665           277              1.26
  SMARCA4                                       11.18   0.000992       2696          1115             1.27
  SFN                                           11.03   0.001026       1008          55               4.19

AvgExp means average expression.

log~2~⁡FC means log~2~⁡ fold change.

###### 

Top 30 proteins of total-stage liver cancer.

  Protein     CRV            *p* value   Case_AvgExp   Control_AvgExp   log~2~⁡FC
  ----------- -------------- ----------- ------------- ---------------- -----------
  APP         81.53          \<10^−9^    14385         14041            0.03
  ELAVL1      3.65*E* + 01   0.000187    1757          1319             0.41
  CCDC33      2.82*E* + 01   0.000464    3             1                1.7
  UBC         25.19          0.000588    35625         35490            0.01
  HIST3H3     24.3           0.000626    1             1                0.02
  KRTAP10-1   23.96          0.000643    1             1                0.02
  ESR1        23.79          0.000652    236           1537             −2.7
  UBD         23.34          0.000682    14701         1781             3.04
  H2AFX       17.28          0.001125    705           271              1.38
  KRTAP10-5   17.05          0.001133    1             1                0.05
  HGS         15.2           0.001329    2473          1167             1.08
  TRAF2       14.28          0.001461    581           277              1.07
  HSP90AB1    14.16          0.001483    29756         14629            1.02
  PCNA        13.58          0.001572    1962          904              1.12
  SMARCA4     13.21          0.001611    2546          1115             1.19
  TAF6        12.84          0.001636    1075          478              1.17
  SUMO2       12.6           0.001704    2968          2112             0.49
  UBQLN4      12.59          0.001713    1881          905              1.05
  COPS5       12.45          0.001743    1604          1184             0.44
  CEP250      12.41          0.001747    673           268              1.33
  EZH2        12.15          0.001802    351           49               2.84
  CDK1        11.69          0.001892    462           34               3.78
  TCF3        11.35          0.00199     980           415              1.24
  CDC20       11.28          0.002011    519           20               4.7
  MCM2        10.9           0.002126    1220          174              2.81
  GRB2        10.64          0.002233    3488          2608             0.42
  WHSC1       10.5           0.002288    1291          447              1.53
  MYOD1       10.5           0.002292    2             1                1.22
  AURKB       10.48          0.002305    169           14               3.61
  SUMO1       10.36          0.002373    2520          2982             −0.24

###### 

The intersection of the total-stage liver cancer with our previous result.

  -----------------------------------------------------------------------
  Protein   CRV\              *p* value\        CRV\         *p* value\
            (in this study)   (in this study)   (previous)   (previous)
  --------- ----------------- ----------------- ------------ ------------
  BUB1B     7.58              0.005833          5.5696       0.00064

  CDC20     11.28             0.002011          5.1507       0.00109

  CDK2      6.9               0.007708          14.069       \<1*E* − 5

  CUL3      8.16              0.004478          12.9519      \<1*E* − 5

  E2F1      10.19             0.002497          3.9947       0.00862

  ESR1      23.79             0.000652          10.3758      \<1*E* − 5

  HDAC4     10.11             0.002531          5.8397       0.00048

  HGS       15.2              0.001329          4.6929       0.00232

  MYC       7.55              0.005884          10.7821      \<1*E* − 5

  PCNA      13.58             0.001572          15.1438      \<1*E* − 5

  PRKDC     8.19              0.004418          5.9369       0.00041

  SMARCA4   13.21             0.001611          7.7449       0.0001

  SUMO1     10.36             0.002373          15.8533      \<1*E* − 5

  TRAF2     14.28             0.001461          4.7703       0.00207

  UBC       25.19             0.000588          137.284      \<1*E* − 5
  -----------------------------------------------------------------------

###### 

\(a\) The pathways analysis for 74 significant proteins in the total stage carcinogenesis. (b) The pathway analysis and gene set enrichment analysis of the 74 proteins of total-stage liver cancer on (1) biological processes, (2) cellular components, and (3) molecular functions by NOA.

  Rank       Term                                                                           Count   Symbol                                                                                   *p* value
  ---------- ------------------------------------------------------------------------------ ------- ---------------------------------------------------------------------------------------- --------------
  KEGG                                                                                                                                                                                       
  1          hsa04110:Cell cycle                                                            14      E2F1, CDK1, PRKDC, CDC20, MCM2, MCM3, YWHAE, MCM4, CDK2, MCM7, GSK3B, PCNA, BUB1B, MYC   5.96*E* − 13
  2          hsa05215:Prostate cancer                                                       7       E2F1, HSP90AB1, GRB2, GSK3B, MAPK3, PTEN, CDK2                                           2.62*E* − 05
  3          hsa04114:Oocyte meiosis                                                        7       CDK1, PPP1CA, MAPK3, CDC20, AURKA, YWHAE, CDK2                                           8.70*E* − 05
  4          hsa03030:DNA replication                                                       5       MCM7, PCNA, MCM2, MCM3, MCM4                                                             9.48*E* − 05
  5          hsa05200:Pathways in cancer                                                    10      E2F1, HSP90AB1, TRAF2, GRB2, MSH2, GSK3B, MAPK3, MYC, PTEN, CDK2                         2.73*E* − 04
  6          hsa05213:Endometrial cancer                                                    5       GRB2, GSK3B, MAPK3, MYC, PTEN                                                            4.03*E* − 04
  7          hsa05210:Colorectal cancer                                                     5       GRB2, MSH2, GSK3B, MAPK3, MYC                                                            0.002457
  8          hsa05222:Small cell lung cancer                                                5       E2F1, TRAF2, MYC, PTEN, CDK2                                                             0.002457
  9          hsa05214:Glioma                                                                4       E2F1, GRB2, MAPK3, PTEN                                                                  0.008946
  10         hsa04722:Neurotrophin signaling pathway                                        5       GRB2, GSK3B, MAPK3, YWHAE, TP73                                                          0.009832
  11         hsa04115:p53 signaling pathway                                                 4       CDK1, PTEN, CDK2, TP73                                                                   0.011029
  12         hsa05220:Chronic myeloid leukemia                                              4       E2F1, GRB2, MAPK3, MYC                                                                   0.014381
  13         hsa04914:Progesterone-mediated oocyte maturation                               4       HSP90AB1, CDK1, MAPK3, CDK2                                                              0.020705
  14         hsa04012:ErbB signaling pathway                                                4       GRB2, GSK3B, MAPK3, MYC                                                                  0.021345
  15         hsa04540:Gap junction                                                          4       CDK1, GRB2, MAPK3, TUBA1B                                                                0.022657
  16         hsa05219:Bladder cancer                                                        3       E2F1, MAPK3, MYC                                                                         0.033366
  17         hsa04510:Focal adhesion                                                        5       PPP1CA, GRB2, GSK3B, MAPK3, PTEN                                                         0.047655
  18         hsa05223:Non-small cell lung cancer                                            3       E2F1, GRB2, MAPK3                                                                        **0.052694**
  19         hsa05221:Acute myeloid leukemia                                                3       GRB2, MAPK3, MYC                                                                         **0.059845**
  20         hsa04910:Insulin signaling pathway                                             4       PPP1CA, GRB2, GSK3B, MAPK3                                                               **0.064636**
  21         hsa05218:Melanoma                                                              3       E2F1, MAPK3, PTEN                                                                        **0.085159**
  22         hsa04662:B cell receptor signaling pathway                                     3       GRB2, GSK3B, MAPK3                                                                       **0.09351**
                                                                                                                                                                                             
  BioCarte                                                                                                                                                                                   
  1a         h_g1Pathway:Cell Cycle:G~1~/S Check Point                                      4       E2F1, CDK1, GSK3B, CDK2                                                                  0.012616
  2a         h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression   3       E2F1, NEDD8, CDK2                                                                        0.020162
  3a         h_p53Pathway:p53 Signaling Pathway                                             3       E2F1, PCNA, CDK2                                                                         0.033691
  4a         h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology                3       GRB2, MAPK3, ESR1                                                                        0.049866
  5a         h_ptenPathway:PTEN dependent cell cycle arrest and apoptosis                   3       GRB2, MAPK3, PTEN                                                                        **0.054277**
  6a         h_RacCycDPathway:Influence of Ras and Rho proteins on G~1~ to S Transition     3       E2F1, MAPK3, CDK2                                                                        **0.063496**
  7a         h_cellcyclePathway:Cyclins and Cell Cycle Regulation                           3       E2F1, CDK1, CDK2                                                                         **0.068295**

The significant pathways via DAVID Bioinformatics database are selected for the 74 significant proteins in carcinogenesis. Bold indicates *p* value \> 0.05. Most of them are from the KEGG database, and we add several key pathways from BioCarta.

  GO:term                      *p* value     Corrected *p* value   *R*    *T*   *G*    *O*   Term name
  ---------------------------- ------------- --------------------- ------ ----- ------ ----- ----------------------------------------------------------
  \(1\) Biological processes                                                                 
  GO:0051320                   9.1*E* − 10   1.9*E* − 7            6357   9     12     4     S phase
  GO:0000084                   9.1*E* − 10   1.9*E* − 7            6357   9     12     4     S phase of mitotic cell cycle
  GO:0006267                   3.3*E* − 9    7.1*E* − 7            6357   9     16     4     Prereplicative complex assembly
  GO:0065004                   1.4*E* − 8    3.1*E* − 6            6357   9     68     5     Protein-DNA complex assembly
  GO:0000727                   2.7*E* − 8    5.8*E* − 6            6357   9     26     4     Double-strand break repair via break-induced replication
  GO:0006270                   3.7*E* − 8    8.0*E* − 6            6357   9     28     4     DNA-dependent DNA replication initiation
  GO:0022616                   5.7*E* − 8    1.2*E* − 5            6357   9     31     4     DNA strand elongation
  GO:0006271                   5.7*E* − 8    1.2*E* − 5            6357   9     31     4     DNA strand elongation involved in DNA replication
  GO:0000724                   1.3*E* − 7    2.8*E* − 5            6357   9     38     4     Double-strand break repair via homologous recombination
  GO:0022402                   2.5*E* − 7    5.3*E* − 5            6357   9     445    7     Cell cycle process
                                                                                             
  \(2\) Cellular components                                                                  
  GO:0042555                   2.7*E* − 11   1.3*E* − 9            6357   9     6      4     MCM complex
  GO:0005656                   3.3*E* − 9    1.5*E* − 7            6357   9     16     4     Prereplicative complex
  GO:0031261                   1.3*E* − 8    6.3*E* − 7            6357   9     22     4     DNA replication preinitiation complex
  GO:0031298                   2.3*E* − 8    1.0*E* − 6            6357   9     25     4     Replication fork protection complex
  GO:0032993                   2.9*E* − 7    1.3*E* − 5            6357   9     46     4     Protein-DNA complex
  GO:0043234                   9.7*E* − 7    4.5*E* − 5            6357   9     1369   9     Protein complex
  GO:0044454                   4.9*E* − 6    2.3*E* − 4            6357   9     217    5     Nuclear chromosome part
  GO:0044451                   1.5*E* − 5    7.5*E* − 4            6357   9     275    5     Nucleoplasm part
  GO:0044428                   1.6*E* − 5    7.7*E* − 4            6357   9     1251   8     Nuclear part
  GO:0044427                   2.5*E* − 5    0.0011                6357   9     302    5     Chromosomal part
                                                                                             
  \(3\) Molecular functions                                                                  
  GO:0043566                   3.8*E* − 10   2.6*E* − 8            6357   9     85     6     Structure-specific DNA binding
  GO:0043138                   5.6*E* − 9    3.7*E* − 7            6357   9     18     4     3′-5′ DNA helicase activity
  GO:0004003                   2.7*E* − 8    1.8*E* − 6            6357   9     26     4     ATP-dependent DNA helicase activity
  GO:0003682                   3.3*E* − 8    2.2*E* − 6            6357   9     80     5     Chromatin binding
  GO:0003688                   4.9*E* − 8    3.3*E* − 6            6357   9     30     4     DNA replication origin binding
  GO:0003678                   1.4*E* − 7    9.9*E* − 6            6357   9     39     4     DNA helicase activity
  GO:0003697                   2.4*E* − 7    1.6*E* − 5            6357   9     44     4     Single-stranded DNA binding
  GO:0016887                   4.9*E* − 7    3.3*E* − 5            6357   9     278    6     ATPase activity
  GO:0043140                   5.5*E* − 7    3.7*E* − 5            6357   9     13     3     ATP-dependent 3′-5′ DNA helicase activity
  GO:0008094                   1.3*E* − 6    9.1*E* − 5            6357   9     67     4     DNA-dependent ATPase activity

*R*: number of genes in reference set.

*T*: number of genes in test set.

*G*: number of genes annotated by given term in reference set.

*O*: number of genes annotated by given term in test set.

###### 

\(a\) The pathways analysis for 43 early stage significant proteins in carcinogenesis. (b) The pathway analysis and gene set enrichment analysis of the 74 proteins of total-stage liver cancer on (1) biological processes, (2) cellular components, and (3) molecular functions by NOA.

  Rank       Term                                                                       Count   Symbol                                                                  *p* value
  ---------- -------------------------------------------------------------------------- ------- ----------------------------------------------------------------------- --------------
  KEGG                                                                                                                                                                  
  1          hsa04110:Cell cycle                                                        11      E2F1, CCNB1, CDK1, CDKN2A, PCNA, BUB1B, PRKDC, CDC20, MCM2, MCM4, MYC   4.90*E* − 11
  2          hsa03030:DNA replication                                                   4       POLD1, PCNA, MCM2, MCM4                                                 5.24*E* − 04
  3          hsa05220:Chronic myeloid leukemia                                          4       E2F1, CDKN2A, GRB2, MYC                                                 0.004415
  4          hsa04114:Oocyte meiosis                                                    4       CCNB1, CDK1, CDC20, AURKA                                               0.01273
  5          hsa05219:Bladder cancer                                                    3       E2F1, CDKN2A, MYC                                                       0.015099
  6          hsa05223:Non-small cell lung cancer                                        3       E2F1, CDKN2A, GRB2                                                      0.024285
  7          hsa05214:Glioma                                                            3       E2F1, CDKN2A, GRB2                                                      0.03234
  8          hsa04115:p53 signaling pathway                                             3       CCNB1, CDK1, CDKN2A                                                     0.037212
  9          hsa03430:Mismatch repair                                                   2       POLD1, PCNA                                                             0.09922
                                                                                                                                                                        
  BioCarta                                                                                                                                                              
  1a         h_cellcyclePathway:Cyclins and Cell Cycle Regulation                       4       E2F1, CCNB1, CDK1, CDKN2A                                               0.002246
  2a         h_srcRPTPPathway:Activation of Src by Protein-tyrosine phosphatase alpha   3       CCNB1, CDK1, GRB2                                                       0.004
  3a         h_g2Pathway:Cell Cycle:G~2~/M Checkpoint                                   3       CCNB1, CDK1, PRKDC                                                      0.025668
  4a         h_g1Pathway:Cell Cycle:G~1~/S Check Point                                  3       E2F1, CDK1, CDKN2A                                                      0.039621
  5a         h_ptc1Pathway:Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle      2       CCNB1, CDK1                                                             **0.075537**

The significant pathways via DAVID Bioinformatics database are selected for the 43 significant proteins in carcinogenesis. Bold indicates *p* value \> 0.05. Most of them are from the KEGG database, and we add several key pathways from BioCarta.

  GO:term                      *p* value    Corrected *p* value   *R*    *T*   *G*    *O*   Term name
  ---------------------------- ------------ --------------------- ------ ----- ------ ----- ----------------------------------------------------------
  \(1\) Biological processes                                                                
  GO:0051320                   1.9*E* − 5   0.0028                6357   4     12     2     S phase
  GO:0000084                   1.9*E* − 5   0.0028                6357   4     12     2     S phase of mitotic cell cycle
  GO:0006267                   3.5*E* − 5   0.0052                6357   4     16     2     Prereplicative complex assembly
  GO:0000727                   9.6*E* − 5   0.0142                6357   4     26     2     Double-strand break repair via break-induced replication
  GO:0006270                   1.1*E* − 4   0.0165                6357   4     28     2     DNA-dependent DNA replication initiation
  GO:0022616                   1.3*E* − 4   0.0203                6357   4     31     2     DNA strand elongation
  GO:0006271                   1.3*E* − 4   0.0203                6357   4     31     2     DNA strand elongation involved in DNA replication
  GO:0000724                   2.0*E* − 4   0.0306                6357   4     38     2     Double-strand break repair via homologous recombination
  GO:0000725                   3.1*E* − 4   0.0470                6357   4     47     2     Recombinational repair
  GO:0022403                   3.4*E* − 4   0.0515                6357   4     286    3     Cell cycle phase
                                                                                            
  \(2\) Cellular components                                                                 
  GO:0042555                   4.4*E* − 6   1.3*E* − 4            6357   4     6      2     MCM complex
  GO:0005656                   3.5*E* − 5   0.0010                6357   4     16     2     Prereplicative complex
  GO:0031261                   6.8*E* − 5   0.0020                6357   4     22     2     DNA replication preinitiation complex
  GO:0031298                   8.8*E* − 5   0.0026                6357   4     25     2     Replication fork protection complex
  GO:0032993                   3.0*E* − 4   0.0091                6357   4     46     2     Protein-DNA complex
  GO:0000151                   5.7*E* − 4   0.0171                6357   4     63     2     Ubiquitin ligase complex
  GO:0043234                   0.0021       0.0643                6357   4     1369   4     Protein complex
  GO:0033597                   0.0025       0.0754                6357   4     4      1     Mitotic checkpoint complex
  GO:0031463                   0.0031       0.0942                6357   4     5      1     Cul3-RING ubiquitin ligase complex
  GO:0043596                   0.0062       0.1883                6357   4     10     1     Nuclear replication fork
                                                                                            
  \(3\) Molecular functions                                                                 
  GO:0043138                   4.5*E* − 5   0.0021                6357   4     18     2     3′-5′ DNA helicase activity
  GO:0004003                   9.6*E* − 5   0.0046                6357   4     26     2     ATP-dependent DNA helicase activity
  GO:0003688                   1.2*E* − 4   0.0061                6357   4     30     2     DNA replication origin binding
  GO:0003678                   2.1*E* − 4   0.0104                6357   4     39     2     DNA helicase activity
  GO:0003697                   2.7*E* − 4   0.0133                6357   4     44     2     Single-stranded DNA binding
  GO:0008094                   6.4*E* − 4   0.0310                6357   4     67     2     DNA-dependent ATPase activity
  GO:0003682                   9.2*E* − 4   0.0443                6357   4     80     2     Chromatin binding
  GO:0043566                   0.0010       0.0500                6357   4     85     2     Structure-specific DNA binding
  GO:0004842                   0.0010       0.0500                6357   4     85     2     Ubiquitin-protein ligase activity
  GO:0070035                   0.0010       0.0511                6357   4     86     2     Purine NTP-dependent helicase activity

*R*: number of genes in reference set.

*T*: number of genes in test set.

*G*: number of genes annotated by given term in reference set.

*O*: number of genes annotated by given term in test set.

###### 

\(a\) The pathways analysis for 80 late stage significant proteins in carcinogenesis. (b) The pathway analysis and gene set enrichment analysis of the 74 proteins of total-stage liver cancer on (1) biological processes, (2) cellular components, and (3) molecular functions by NOA.

  Rank       Term                                                                             Count   Symbol                                                                                                *p* value
  ---------- -------------------------------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------- --------------
  KEGG                                                                                                                                                                                                      
  1          hsa04110:Cell cycle                                                              16      E2F1, CDK1, YWHAZ, YWHAB, CDC20, SFN, MCM2, MCM3, CDK4, MCM4, CDK2, MCM7, PCNA, YWHAQ, BUB1B, CCNA2   3.90*E* − 14
  2          hsa04114:Oocyte meiosis                                                          8       CDK1, YWHAZ, YWHAB, YWHAQ, CDC20, AURKA, PPP1CC, CDK2                                                 3.62*E* − 05
  3          hsa03030:DNA replication                                                         5       MCM7, PCNA, MCM2, MCM3, MCM4                                                                          2.35*E* − 04
  4          hsa04115:p53 signaling pathway                                                   4       CDK1, SFN, CDK4, CDK2                                                                                 0.020496
  5          hsa03040:Spliceosome                                                             5       SNRPB, THOC4, LSM2, SF3A2, SF3B4                                                                      0.022722
  6          hsa05222:Small cell lung cancer                                                  4       E2F1, TRAF2, CDK4, CDK2                                                                               0.035432
  7          hsa04914:Progesterone-mediated oocyte maturation                                 4       HSP90AB1, CDK1, CCNA2, CDK2                                                                           0.037607
  8          hsa00310:Lysine degradation                                                      3       SETDB1, WHSC1, EHMT2                                                                                  **0.055046**
  9          hsa05200:Pathways in cancer                                                      7       E2F1, HSP90AB1, TRAF2, MSH2, BIRC5, CDK4, CDK2                                                        **0.061178**
                                                                                                                                                                                                            
  BioCarte                                                                                                                                                                                                  
  1a         h_p53Pathway:p53 Signaling Pathway                                               4       E2F1, PCNA, CDK4, CDK2                                                                                0.003378
  2a         h_cellcyclePathway:Cyclins and Cell Cycle Regulation                             4       E2F1, CDK1, CDK4, CDK2                                                                                0.010334
  3a         h_g1Pathway:Cell Cycle:G~1~/S Check Point                                        4       E2F1, CDK1, CDK4, CDK2                                                                                0.015615
  4a         h_rbPathway:RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage   3       CDK1, CDK4, CDK2                                                                                      0.019987
  5a         h_ranMSpathway:Role of Ran in mitotic spindle regulation                         3       RAN, AURKA, KPNA2                                                                                     0.019987
  6a         h_g2Pathway:Cell Cycle:G~2~/M Checkpoint                                         3       CDK1, YWHAQ, BRCA1                                                                                    **0.067509**
  7a         h_RacCycDPathway:Influence of Ras and Rho proteins on G~1~ to S Transition       3       E2F1, CDK4, CDK2                                                                                      **0.072809**

The significant pathways via DAVID Bioinformatics database are selected for the 74 significant proteins in carcinogenesis. Bold indicates *p* value \> 0.05. Most of them are from the KEGG database, and we add several key pathways from BioCarta.

  GO:term                      *p* value     Corrected *p* value   *R*    *T*   *G*    *O*   Term name
  ---------------------------- ------------- --------------------- ------ ----- ------ ----- ----------------------------------------------------------
  \(1\) Biological processes                                                                 
  GO:0051320                   1.5*E* − 9    3.6*E* − 7            6357   10    12     4     S phase
  GO:0000084                   1.5*E* − 9    3.6*E* − 7            6357   10    12     4     S phase of mitotic cell cycle
  GO:0006267                   5.5*E* − 9    1.3*E* − 6            6357   10    16     4     Prereplicative complex assembly
  GO:0000727                   4.5*E* − 8    1.1*E* − 5            6357   10    26     4     Double-strand break repair via break-induced replication
  GO:0006270                   6.2*E* − 8    1.5*E* − 5            6357   10    28     4     DNA-dependent DNA replication initiation
  GO:0022616                   9.5*E* − 8    2.3*E* − 5            6357   10    31     4     DNA strand elongation
  GO:0006271                   9.5*E* − 8    2.3*E* − 5            6357   10    31     4     DNA strand elongation involved in DNA replication
  GO:0000724                   2.2*E* − 7    5.4*E* − 5            6357   10    38     4     Double-strand break repair via homologous recombination
  GO:0006260                   5.1*E* − 7    1.2*E* − 4            6357   10    120    5     DNA replication
  GO:0000725                   5.3*E* − 7    1.2*E* − 4            6357   10    47     4     Recombinational repair
                                                                                             
  \(2\) Cellular components                                                                  
  GO:0042555                   4.6*E* − 11   2.2*E* − 9            6357   10    6      4     MCM complex
  GO:0005656                   5.5*E* − 9    2.6*E* − 7            6357   10    16     4     Prereplicative complex
  GO:0031261                   2.2*E* − 8    1.0*E* − 6            6357   10    22     4     DNA replication preinitiation complex
  GO:0031298                   3.8*E* − 8    1.8*E* − 6            6357   10    25     4     Replication fork protection complex
  GO:0032993                   4.8*E* − 7    2.3*E* − 5            6357   10    46     4     Protein-DNA complex
  GO:0044454                   2.3*E* − 4    0.0113                6357   10    217    4     Nuclear chromosome part
  GO:0044451                   5.8*E* − 4    0.0280                6357   10    275    4     Nucleoplasm part
  GO:0044428                   7.7*E* − 4    0.0370                6357   10    1251   7     Nuclear part
  GO:0044427                   8.3*E* − 4    0.0400                6357   10    302    4     Chromosomal part
  GO:0043234                   0.0013        0.0656                6357   10    1369   7     Protein complex
                                                                                             
  \(3\) Molecular functions                                                                  
  GO:0043138                   9.3*E* − 9    6.4*E* − 7            6357   10    18     4     3′-5′ DNA helicase activity
  GO:0004003                   4.5*E* − 8    3.1*E* − 6            6357   10    26     4     ATP-dependent DNA helicase activity
  GO:0003688                   8.3*E* − 8    5.7*E* − 6            6357   10    30     4     DNA replication origin binding
  GO:0043566                   9.0*E* − 8    6.2*E* − 6            6357   10    85     5     Structure-specific DNA binding
  GO:0003678                   2.4*E* − 7    1.7*E* − 5            6357   10    39     4     DNA helicase activity
  GO:0003697                   4.0*E* − 7    2.8*E* − 5            6357   10    44     4     Single-stranded DNA binding
  GO:0043140                   7.9*E* − 7    5.4*E* − 5            6357   10    13     3     ATP-dependent 3′-5′ DNA helicase activity
  GO:0008094                   2.2*E* − 6    1.5*E* − 4            6357   10    67     4     DNA-dependent ATPase activity
  GO:0003682                   4.6*E* − 6    3.1*E* − 4            6357   10    80     4     Chromatin binding
  GO:0070035                   6.1*E* − 6    4.2*E* − 4            6357   10    86     4     Purine NTP-dependent helicase activity

*R*: number of genes in reference set.

*T*: number of genes in test set.

*G*: number of genes annotated by given term in reference set.

*O*: number of genes annotated by given term in test set.
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